尚乘數科上市12天暴漲108.6倍,市值僅次於臺積電、阿裏
中概股尚乘數科延續上市以來的瘋漲勢頭,今日盤前,尚乘數科漲15.23%,報855.00美元,股價波動異常,投資者需提防炒作風險。
據統計,尚乘數科自2022年7月15日紐交所上市至今,上市12個交易日,股價已從發行價7.80美元飆升到847.3美元,累計漲幅達108.6倍。在一衆中概股裏面,尚乘數科市值排名第三,僅次於臺積電、阿裏巴巴。
據瞭解,尚乘數科爲尚乘集團旗下企業,而尚乘集團則是由李嘉誠的長江實業集團和和記黃埔在2003年創立,是亞洲最大的民營獨立投資銀行,也是香港領先的綜合性金融機構集團和最大的獨立非銀行資產管理公司和保險經紀公司之一。此次赴美上市的尚乘數科由同爲集團子公司的尚乘國際(HKIB)分拆而來,後者於2019年在紐交所上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.